Azvudine is under clinical development by Henan Genuine Biotech and currently in Phase I for Human Immunodeficiency Virus (HIV) Infections (AIDS). According to GlobalData, Phase I drugs for Human Immunodeficiency Virus (HIV) Infections (AIDS) have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Azvudine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Azvudine overview

Azvudine is an anti viral agent. It is formulated as tablets for oral route of administration. Azvudine is used in combination with nucleoside reverse transcriptase inhibitors and non-nucleoside reverse transcriptase inhibitors to treat adult HIV-1 infected patients with high viral loads and also targets Vif protein (virion infectivity factor) of HIV-1, HBV. Azvudine is indicated for the treatment of common new coronavirus pneumonia in adult patients.

It was under development for the treatment of hepatitis B, multiple myeloma, lymphoma, coronavirus disease 2019 (COVID-19) and acute leukemia. 

Henan Genuine Biotech overview

Henan Genuine Biotech (Genuine Biotech) is a biopharmaceutical company engaged in discovery, clinical research and development, and commercialization of drugs such as antiviral, antitumor, and for the treatment of cardiovascular, cerebrovascular and liver diseases.

For a complete picture of Azvudine’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.